This guide is about regulatory status and consumer verification, not about deciding whether hormone therapy is appropriate for any individual. Menopause hormone therapy has potential benefits and risks, and a licensed clinician should make treatment decisions using the person’s medical history, symptoms, other medications, and relevant risk factors.

Compare online menopause and HRT programs · See how Care Path Compare verifies providers

The short version

The key question is not natural versus synthetic or online versus in-person. It is the regulatory status of the exact product a clinician prescribes and a pharmacy dispenses.

An FDA-approved hormone product has gone through FDA’s premarket approval process for that product and approved use. A compounded hormone product has not. Compounding can have a legitimate clinical role, but the finished compounded drug is not FDA-approved and does not receive the same premarket review.

The term bioidentical can describe products in either category. FDA-approved estradiol or progesterone products can be described as bioidentical, and custom-compounded hormone preparations are also commonly marketed with that word.

That is why consumers should verify the exact medication instead of relying on the category label.

Why “bioidentical” does not mean FDA-approved

The Menopause Society explains that bioidentical hormones do not have to be custom compounded and that FDA-approved hormone products can meet the common definition of bioidentical. (The Menopause Society: Hormone Therapy)

ACOG similarly distinguishes commercially available FDA-approved products containing hormones such as estradiol and micronized progesterone from custom-compounded preparations that are not FDA-approved. (ACOG: Compounded Bioidentical Menopausal Hormone Therapy)

A consumer therefore should not infer regulatory status from phrases such as:

  • “bioidentical”;
  • “body-identical”;
  • “natural hormone”;
  • “customized hormone therapy”;
  • “personalized HRT”; or
  • “made by a compounding pharmacy.”

Ask for the exact product name, dosage form, manufacturer or compounding pharmacy, and prescription label.

What FDA-approved means

An FDA-approved drug has gone through the agency’s approval process for the specific product and approved use. FDA reviews evidence and manufacturing information before approval, and approved products have standardized prescribing information.

That does not mean an FDA-approved hormone is automatically appropriate for every patient. FDA’s menopause materials emphasize that hormone therapy has benefits and risks and that treatment decisions should be made with a healthcare professional. (FDA: Menopause)

For a consumer comparing telehealth programs, FDA approval answers a narrow but important question:

Has this exact drug product gone through FDA’s premarket approval process?

It does not determine individual eligibility or replace an individualized clinical evaluation.

What compounded means

Drug compounding generally involves combining, mixing, or altering ingredients to create a medication for a patient’s needs. FDA says compounded drugs can serve an important medical need, but they are not FDA-approved. FDA therefore does not verify the safety, effectiveness, or quality of a compounded finished drug before marketing in the same way it does for an approved drug. (FDA: Compounding and the FDA)

FDA also distinguishes compounded drugs from FDA-approved generic drugs. A compounded drug is not an FDA-approved generic simply because it contains a familiar active ingredient.

That distinction matters when evaluating phrases such as:

  • “generic hormone therapy”;
  • “same active ingredient”;
  • “equivalent to” an approved product; or
  • “custom version” of an approved drug.

Those phrases do not by themselves establish FDA approval or therapeutic equivalence.

FDA also warns that poor compounding practices can create quality problems. That does not mean every compounded drug is unsafe or that compounding has no legitimate role. It means the regulatory pathway and premarket review are different.

503A and 503B are not the same

Online HRT programs may mention a 503A pharmacy or a 503B outsourcing facility. Those terms describe different parts of federal compounding law; neither term means the finished compounded drug is FDA-approved.

Section 503A

Section 503A generally applies to qualifying compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, often based on a patient-specific prescription. FDA explains that state boards of pharmacy generally have primary day-to-day oversight of state-licensed pharmacies that are not registered outsourcing facilities, while FDA can conduct surveillance and for-cause inspections.

Section 503B

Section 503B created a category called an outsourcing facility. FDA says registered outsourcing facilities are subject to additional federal requirements, including current good manufacturing practice requirements, adverse-event reporting, and risk-based FDA inspection.

But registration or inspection does not make the compounded product FDA-approved. FDA states that products compounded by outsourcing facilities remain unapproved and that registration does not mean FDA has determined a facility is in compliance or approved a specific product. (FDA: Outsourcing Facility Registration Q&A)

Useful questions include:

  1. What is the pharmacy or outsourcing facility’s legal name?
  2. Is it a 503A pharmacy, a 503B outsourcing facility, or another dispensing arrangement?
  3. Is the pharmacy licensed to dispense to the patient’s state?
  4. What exact product will be dispensed?
  5. Is that exact product FDA-approved or compounded?

When compounding can serve a medical need

FDA says compounding can serve an important medical need when an FDA-approved medication cannot meet a patient’s needs. One example is when a patient needs a different formulation because an ingredient in an approved product is unsuitable. (FDA: Compounding and the FDA)

ACOG also recognizes that compounding can be appropriate in some circumstances. Its clinical consensus gives examples in which a commercially available product may contain an ingredient a patient cannot use or a different formulation is medically needed.

The useful consumer question is not whether all compounding is good or bad. It is:

Why is this compounded product being offered for this patient, and what approved alternatives were considered?

That is a question for the prescribing clinician, not for an affiliate page or pricing table.

How major medical groups frame the choice

ACOG’s current clinical consensus says compounded bioidentical menopausal hormone therapy should not be routinely prescribed when FDA-approved formulations exist. It recommends counseling patients that FDA-approved menopausal hormone therapies are preferred over custom-compounded bioidentical preparations for routine management of menopausal symptoms. (ACOG clinical consensus)

The Menopause Society similarly says custom-compounded hormones have not been shown to be safer or more effective than approved bioidentical hormone products and highlights concerns about predictable dosing and product consistency. (The Menopause Society: Hormone Therapy)

Those are professional-organization recommendations. Care Path Compare is not turning them into an individualized treatment recommendation. A clinician still has to evaluate the patient’s circumstances and exact product under consideration.

Marketing phrases that need a second look

Telehealth advertising can compress complicated regulatory facts into short phrases. None of these phrases alone answers whether the specific drug product is FDA-approved.

“FDA-registered facility”

A facility can have an FDA registration relationship without each product it makes being FDA-approved. For 503B outsourcing facilities, FDA specifically says registration does not equal approval of compounded drug products.

“FDA-inspected”

Inspection describes oversight of a facility. It does not convert a compounded drug into an FDA-approved product.

“State-licensed pharmacy”

State licensure is important and should be verified. But a state pharmacy license and FDA drug approval answer different questions.

“Bioidentical”

Some FDA-approved hormone products can be described as bioidentical; many compounded hormone products are also marketed with that word. The label alone does not determine FDA status.

“Same active ingredient”

Having the same or a similar active ingredient does not by itself make a compounded product an FDA-approved generic or establish therapeutic equivalence.

“Personalized” or “customized”

Customization may be clinically relevant in some circumstances, but it does not establish that a product is safer, more effective, or FDA-approved.

What to verify with an online HRT program

Before paying for an online menopause program, ask for written answers where possible.

Medication status

  • What is the exact medication name?
  • Is the exact dispensed product FDA-approved or compounded?
  • If compounded, what active ingredient, dosage form, and strength appear on the prescription label?
  • Is the product being described as a generic, an approved drug, or a compounded preparation?

Prescriber and clinical process

  • Who makes the prescribing decision?
  • Is the clinician licensed or otherwise permitted to provide care in the patient’s state?
  • Does payment occur before or after clinical review?
  • What happens financially if the clinician decides not to prescribe?

Pharmacy and fulfillment

  • What is the dispensing pharmacy’s legal name and location?
  • Is it a state-licensed 503A pharmacy, a 503B outsourcing facility, or another pharmacy arrangement?
  • Can the pharmacy legally dispense to the patient’s state?
  • Is pharmacist contact information available for medication questions?

Why this product is being offered

If the program offers a compounded product when FDA-approved options exist, a patient can ask the clinician why the compounded product is being considered and whether an FDA-approved option could meet the same clinical need.

That question does not assume the compounded option is inappropriate. It asks the prescriber to explain the clinical rationale and alternatives.

Commercial terms

Regulatory status and billing should be checked separately. Also verify:

  • consultation or membership fees;
  • medication cost;
  • laboratory charges;
  • shipping charges;
  • recurring billing date;
  • cancellation deadline; and
  • refund treatment if a prescription is not issued or a product is unavailable.

A medication can be FDA-approved while a telehealth program still has confusing billing terms, and transparent billing does not establish the regulatory status of a drug.

How this applies to Care Path Compare’s HRT reviews

Care Path Compare records the regulatory status of the specific medication pathway whenever it is reasonably verifiable. We do not infer that every medication sold by a telehealth company has the same status.

A provider may offer FDA-approved manufactured hormone products in one pathway and compounded products in another. In that situation, the provider should not be labeled simply “FDA-approved” or “compounded.” The exact product and dispensing arrangement matter.

Our online menopause and HRT comparison uses this distinction when comparing treatment models. Our Gala Health HRT review and Hone Health women’s HRT review apply the same verification rule at the provider level.

Frequently asked questions

Are all bioidentical hormones compounded?

No. FDA, ACOG, and The Menopause Society distinguish FDA-approved hormone products containing hormones identical to those made by the body from custom-compounded hormone preparations. Bioidentical terminology alone does not tell you whether a product is FDA-approved.

Are compounded menopause hormones FDA-approved?

No. FDA states that compounded drugs are not FDA-approved. They do not undergo FDA’s premarket approval review for safety, effectiveness, and quality as finished drug products.

Is a 503B outsourcing facility FDA-approved?

A 503B outsourcing facility can register with FDA and is subject to additional federal requirements and inspections. FDA states that this registration does not mean its compounded drug products are FDA-approved or that the facility has been determined to be fully compliant.

Is a compounded drug the same as an FDA-approved generic?

No. FDA distinguishes the categories. FDA-approved generic drugs must meet approval requirements, including therapeutic-equivalence requirements. A compounded drug is not an FDA-approved generic simply because it uses a similar active ingredient.

Why would a clinician prescribe a compounded hormone product?

FDA and ACOG recognize that compounding can serve a medical need in some circumstances, such as when an FDA-approved product cannot meet a patient’s specific medical needs. Whether that applies to an individual should be determined by the licensed prescriber.

Does receiving HRT through telehealth change whether a drug is FDA-approved?

No. The care-delivery channel does not determine drug approval status. The exact product either has FDA approval or it does not. Telehealth adds separate questions about clinician licensure, pharmacy fulfillment, state availability, privacy, and billing.

Source notes

Care Path Compare checked the cited FDA, ACOG, and Menopause Society materials on September 18, 2026.

Primary references:

This page is educational and does not provide medical advice, determine eligibility, recommend a product, or replace a discussion with a licensed healthcare professional.